Skip to main content
SpringerLink
Log in

Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma

  • Review article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic ductal adenocarcinoma, allowing the early application of systemic therapies, has also increased. However, treatment selection fundamentally depends on decisions taken by multidisciplinary committees due to the absence of randomized trials on this indication and because the available evidence is based primarily on small studies. The present manuscript tries to establish recommendations based on the available evidence and expert opinion to correctly select the indication, the type of treatment, as well as its duration and how to correctly follow-up patients during treatment with chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed Feb 2016.

  2. GLOBOCAN. European age-standardised rates calculated by the statistical information team at cancer research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, version 1.2. http://globocan.iarc.fr. Accessed 4 Feb 2016.

  3. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8–18.

    Article  PubMed  Google Scholar 

  4. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.

    Article  CAS  PubMed  Google Scholar 

  5. Gnerlich JL, Luka SR, Deshpande AD, Durbray BJ, Weir JS, Carpenter DH, et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 2012;147:753–60.

    Article  PubMed  Google Scholar 

  6. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.

    Article  PubMed  Google Scholar 

  8. Tran Cao HS, Balachandran A, Wang H, Nogueras-González GM, Bailey CE, Lee JE, et al. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014;18:269–78.

    Article  PubMed  Google Scholar 

  9. Raman SP, Horton KM, Fishman EK. Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J. 2012;18:511–22.

    Article  PubMed  Google Scholar 

  10. Kasumova GG, Eskander MF, Bullock A, Schlechter BJ, Miksad RA, Ng SC, et al. Does clinical stage predict pathologic stage in pancreatic adenocarcinoma? 2016 ASCO Annual Meeting; Chicago, IL, USA. 2016 (suppl; abstr 4118).

  11. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307:26–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kabashima A, Higuchi H, Takaishi H, Matsuzaki Y, Suzuki S, Izumiya M, et al. Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer. 2009;124:2771–9.

    Article  CAS  PubMed  Google Scholar 

  14. Roy LD, Sahraei M, Subramani DB, Besmer D, Naths S, Tinder TL, Bajaj E, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30:1449–59.

    Article  CAS  PubMed  Google Scholar 

  15. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.

    Article  PubMed  Google Scholar 

  16. Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214:33–45.

    Article  PubMed  Google Scholar 

  17. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466–73.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19:1644–62.

    Article  PubMed  Google Scholar 

  20. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–5.

    Article  CAS  PubMed  Google Scholar 

  22. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012;13:497–501.

    PubMed  Google Scholar 

  23. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Emani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54:979–85.

    Article  CAS  PubMed  Google Scholar 

  25. Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295–301.

    Article  CAS  PubMed  Google Scholar 

  26. Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109:926–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouam Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    Article  CAS  PubMed  Google Scholar 

  28. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.

    Article  Google Scholar 

  29. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749–56.

    Article  PubMed  Google Scholar 

  30. Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16:430–8.

    Article  Google Scholar 

  31. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PWT, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794–801.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Roland CL, Katz MH, Tzeng CD, Lin H, Varadhachary GR, Shroff R, et al. The addition of postoperative chemotherapy is associated with improved survival in patients with pancreatic cancer treated with preoperative therapy. Ann Surg Oncol. 2015;22:S1221–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Sofía Perea, Pharm D, Ph.D., for her support in writing the manuscript.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain

    R. Álvarez

  2. Department of Medical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain

    I. Alés

  3. Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    R. Díaz

  4. Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain

    B. G. de Paredes

  5. Beth Israel Deaconness Medical Center, Harvard Medical School, Boston, USA

    M. Hidalgo

Authors
  1. R. Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Alés
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. G. de Paredes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Hidalgo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Álvarez.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

The support for medical writing was supported by Fundación ECO.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Álvarez, R., Alés, I., Díaz, R. et al. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Clin Transl Oncol 19, 1193–1198 (2017). https://doi.org/10.1007/s12094-017-1680-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1680-8

Keywords

Search

Navigation